Quidel Stock Price, News & Analysis

Quidel Corporation has launched a public service campaign to raise awareness about Lyme disease among summer camps as they reopen after two years. The campaign includes educational materials and social media outreach aimed at prevention and early detection. Lyme disease affects about 476,000 Americans annually, often leading to serious complications if not treated promptly. Quidel offers the Sofia® 2 Lyme FIA, a rapid, on-site test delivering results in 15 minutes, enhancing early treatment options. This initiative comes as camps open, reflecting a gradual return to normalcy post-pandemic.

Quidel Corporation's Sofia® 2 Lyme FIA test is gaining traction amid a rising number of Lyme disease cases in the U.S., projected to reach up to 476,000 this year. Various institutions report an unexpected spread of Lyme disease, exacerbated by increased outdoor activity post-COVID restrictions and a warm winter boosting tick populations. The Sofia® 2 Lyme FIA delivers results within 15 minutes instead of days, enabling timely treatment and potentially preventing severe complications of untreated Lyme disease. Quidel emphasizes the importance of early testing to improve patient outcomes.

Quidel Corporation (NASDAQ: QDEL) has received an amended Emergency Use Authorization from the FDA for its new Sofia Q device, which will initially be sold for use with Sofia SARS Antigen FIA tests. This innovative device features a compact design and integrates with a mobile app for easier workflow management and result interpretation. Quidel aims to democratize access to rapid diagnostic testing across various sectors. The Sofia Q enhances the existing Sofia product line, known for its accuracy and efficiency in providing rapid results.

Quidel Corporation (NASDAQ: QDEL) will present at the Raymond James Human Health Innovation Conference 2021 virtually on June 21, 2021, at 1:20 p.m. ET. CEO Douglas Bryant and CFO Randy Steward will discuss the company’s business and financial developments in a Q&A format. The presentation will be accessible via live webcast on the company’s Investor Relations webpage, with a replay available for 14 days. Quidel is a leading provider of rapid diagnostic testing solutions, known for innovation in the medical device industry, including COVID-19 testing.

Quidel Corporation (NASDAQ: QDEL) announced its participation at the William Blair 41st Annual Growth Stock Conference on June 3, 2021. Presenting will be CEO Douglas Bryant and CFO Randy Steward at 10:40 a.m. Central time. The presentation will cover important business trends and developments. A live webcast and audio archive will be accessible via the company’s Investor Relations page. Quidel is a leader in rapid diagnostic solutions, aiming to enhance global healthcare quality.

Quidel Corporation (NASDAQ: QDEL) announces that its Sofia® SARS Antigen FIA has become the first rapid antigen test authorized by Health Canada for serial testing to detect active coronavirus infections in both symptomatic and asymptomatic individuals.

The test, which shows 96.7% agreement with PCR results within the first five days of symptoms, will be utilized every three days for asymptomatic individuals. This approval aims to enhance widespread screening in Canada, vital for controlling COVID-19 transmission and aiding economic recovery.

Quidel Corporation (QDEL) announces the availability of its QuickVue® At-Home OTC COVID-19 Test for online purchase on Amazon. This test allows consumers to self-administer a COVID-19 test and receive results in just 10 minutes. The product shows high accuracy, with positive agreement with PCR tests at 83.5% and negative agreement at 99.2%. A 2-pack is priced at $24.95 with free shipping. The test is available under FDA's Emergency Use Authorization but is not FDA approved.

Quidel Corporation (NASDAQ: QDEL) reported a remarkable 115% revenue increase to $375.3 million for Q1 2021, driven largely by COVID-19 related products, which generated $280.3 million. Net income surged by 340% to $178.1 million, translating to GAAP EPS of $4.09 per diluted share. Sales of Influenza products dropped to $5.2 million from $79.6 million year-on-year. The company received FDA EUAs for QuickVue® At-Home COVID-19 Tests, enhancing its portfolio for at-home testing. Gross profit rose 163% to $302.0 million.

Quidel Corporation (NASDAQ: QDEL) has partnered with Walgreens to distribute its QuickVue® At-Home OTC COVID-19 Test at 7,600 Walgreens stores across the U.S. and Puerto Rico. This collaboration enables consumers to purchase the test over-the-counter, enhancing accessibility. Each kit includes two tests and delivers results within 10 minutes, boasting an agreement rate of 83.5% for positive results with PCR tests. The QuickVue test is authorized under FDA's Emergency Use Authorization, vital in controlling COVID-19 spread.